Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Allograft Tolerance Through Mixed Chimerism
NCT04540380Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2021
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siplizumab in kidney failure (ESRD), sponsored by Massachusetts General Hospital. Primary endpoints: Incidence of Transient Chimerism at 36 months, Incidence of Chimerism Transition Syndrome at 36 months and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
siplizumab
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT04540380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540380.